Diamyd Medical AB (publ) (DMYD-B.ST)
Diamyd Medical AB (publ) operates in the Biotechnology industry of the Healthcare sector, headquartered in Stockholm, AB, SE. The stock last traded at $1.04, down 9.39% on the session, giving a market capitalisation of $157.8M. Its beta of 2.29 implies it has historically moved more than the broad market.
Diamyd Medical AB (publ), a Swedish company founded in Stockholm in 1984, specializes in developing innovative treatments for autoimmune diabetes. Formerly known as Diamyd Therapeutics AB until its name change in April 2013, the company is advancing two key therapeutic candidates. Its flagship product, Diamyd, is an antigen-specific immunotherapy vaccine for diabetes currently undergoing Phase IIb clinical studies for both type 1 diabetes and latent autoimmune diabetes. Additionally, Remygen, an oral drug candidate with regenerative and immunomodulatory properties, is progressing through Phase I/II clinical trials for the treatment of autoimmune and type 2 diabetes.
Diamyd Medical AB (publ) is most often compared with the following Healthcare names: